Decoy Therapeutics Inc. Total Liabilities
Decoy Therapeutics Inc. total liabilities. Based on the latest financial reports, Decoy Therapeutics Inc. (DCOY) has total liabilities worth $4.68 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Decoy Therapeutics Inc. liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Decoy Therapeutics Inc. (2014–2025)
Total liabilities of Decoy Therapeutics Inc. from 2014 to 2025. This chart illustrates how Decoy Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Decoy Therapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Decoy Therapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
XXL Energy Corp
V:XL
|
Canada | CA$54.49 Million |
|
Bango plc
LSE:BGO
|
UK | GBX54.67 Million |
|
Aesthetic Medical International Holdings Group Limited
NASDAQ:PAIYY
|
USA | $554.12 Million |
|
Vast Resources PLC
LSE:VAST
|
UK | GBX32.29 Million |
|
RightBridge Ventures Group AB
ST:RIGHTB
|
Sweden | Skr15.38 Million |
|
Mastrad
PA:ALMAS
|
France | €3.00 Million |
|
Anglo-Eastern Plantations PLC
LSE:AEP
|
UK | GBX70.07 Million |
|
ARCTIC BLUE BEVERAGES AB
F:U5L
|
Germany | €23.26 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Decoy Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Decoy Therapeutics Inc. total assets.
Liquidity & Leverage Metrics
Decoy Therapeutics Inc. Total Liabilities Ratios Explained
Decoy Therapeutics Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Decoy Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Decoy Therapeutics Inc. (2014–2025)
The table below shows the annual total liabilities of Decoy Therapeutics Inc. from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $5.17 Million | +241.94% |
| 2024-12-31 | $1.51 Million | +16.32% |
| 2023-12-31 | $1.30 Million | -69.55% |
| 2022-12-31 | $4.27 Million | +102.10% |
| 2021-12-31 | $2.11 Million | -23.88% |
| 2020-12-31 | $2.77 Million | -16.31% |
| 2019-12-31 | $3.31 Million | +199.33% |
| 2018-12-31 | $1.11 Million | -81.20% |
| 2017-12-31 | $5.89 Million | +51.04% |
| 2016-12-31 | $3.90 Million | +35.45% |
| 2015-12-31 | $2.88 Million | -93.17% |
| 2014-12-31 | $42.15 Million | -- |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverage… Read more